Other Compounds and Targets in Non–Small Cell Lung Cancer

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Druker, 2004, Imatinib as a paradigm of targeted therapies, Adv Cancer Res, 91, 1, 10.1016/S0065-230X(04)91001-9 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR- ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J Natl Cancer Inst, 97, 643, 10.1093/jnci/dji112 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Miller, 2005 Sandler, 2005 O’Connor, 1997, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res, 57, 4285 Amundson, 2000, An informatics approach identifying markers of chemosensitivity in human cancer cell lines, Cancer Res, 60, 6101 Okada, 2004, Pathways of apoptotic and non-apoptotic death in tumour cells, Nat Rev Cancer, 4, 592, 10.1038/nrc1412 Reed, 1999, Dysregulation of apoptosis in cancer, J Clin Oncol, 17, 2941, 10.1200/JCO.1999.17.9.2941 Igney, 2002, Death and anti-death, Nat Rev Cancer, 2, 277, 10.1038/nrc776 Alberts, 2002, 1010 Thun, 1991, Aspirin use and reduced risk of fatal colon cancer, N Engl J Med, 325, 1593, 10.1056/NEJM199112053252301 Lundholm, 1994, Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors, Cancer Res, 54, 5602 Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, 60, 1306 Williams, 2000, Celecoxib prevents tumor growth in vivo without toxicity to normal gut, Cancer Res, 60, 6045 Song, 2002, Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells, J Natl Cancer Inst, 94, 585, 10.1093/jnci/94.8.585 Thompson, 2000, Exisulind induction of apoptosis involves guanosine 3’,5’-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin, Cancer Res, 60, 3338 Taketo, 1998, Cyclooxygenase-2 inhibitors in tumorigenesis (part I), J Natl Cancer Inst, 90, 1529, 10.1093/jnci/90.20.1529 Taketo, 1998, Cyclooxygenase-2 inhibitors in tumorigenesis (part II), J Natl Cancer Inst, 90, 1609, 10.1093/jnci/90.21.1609 Kim, 2004, Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-μB as a possible target, J Cancer Res Clin Oncol, 130, 551, 10.1007/s00432-004-0567-6 Ding, 2005, Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9, Int J Cancer, 113, 803, 10.1002/ijc.20639 Altorki, 2003, Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer, J Clin Oncol, 21, 2645, 10.1200/JCO.2003.07.127 Johnson, 2003, Cyclooxygenase-2 (COX-2) inhibition in non–small cell lung cancer, Proc Am Soc Clin Oncol, 22, 640 Lilenbaum, 2005, Phase II randomized trial of irinotecan/docetaxel or irinotecan/gemcitabine with or without celecoxib in 2nd-line treatment of non–small cell lung cancer, Lung Cancer, 49, S89, 10.1016/S0169-5002(05)80409-X Villaflor, 2003, Potential thromboembolic complications in patients with non-small cell lung cancer treated with paclitaxel, carboplatin, and exisulind, Proc Am Soc Clin Oncol, 22, 706 Masters, 2004, A phase II trial of carboplatin and gemcitabine with exisulind (IND#65,056) in patients with advanced non–small cell lung cancer, Proc Am Soc Clin Oncol, 22, 145 Jones, 2005, A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non–small-cell lung cancer, Clin Lung Cancer, 6, 361, 10.3816/CLC.2005.n.016 O’Byrne, 2004, Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 22, 145 Reckamp, 2005, Targeted COX-2 and EGFR inhibition in advanced NSCLC, Lung Cancer, 49, S65, 10.1016/S0169-5002(05)80329-0 Pisters, 2000, Induction chemotherapy before surgery for early- stage lung cancer, Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg, 119, 429, 10.1016/S0022-5223(00)70120-6 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer (The IDEAL 1 Trial) [corrected], J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038 Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer, JAMA, 290, 2149, 10.1001/jama.290.16.2149 Hershko, 1998, The ubiquitin system, Annu Rev Biochem, 67, 425, 10.1146/annurev.biochem.67.1.425 Desai, 1997, Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin, J Biol Chem, 272, 24159, 10.1074/jbc.272.39.24159 Ciechanover, 1991, Degradation of nuclear oncoproteins by the ubiquitin system in vitro, Proc Natl Acad Sci U S A, 88, 139, 10.1073/pnas.88.1.139 Goldberg, 2003, Protein degradation and protection against misfolded or damaged proteins, Nature, 426, 895, 10.1038/nature02263 Treier, 1994, Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain, Cell, 78, 787, 10.1016/S0092-8674(94)90502-9 Schenkein, 2004, Use of proteasome inhibition in the treatment of lung cancer, Clin Lung Cancer, 6, S89, 10.3816/CLC.2004.s.021 Adams, 1999, Proteasome inhibitors, Cancer Res, 59, 2615 Yang, 2003, Overcoming drug resistance in multiple myeloma, J Clin Oncol, 21, 4239, 10.1200/JCO.2003.06.001 Teicher, 1999, The proteasome inhibitor PS-341 in cancer therapy, Clin Cancer Res, 5, 2638 Mack, 2003, Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer, Lung Cancer, 41, S89, 10.1016/S0169-5002(03)00149-1 Mitsiades, 2002, Molecular sequelae of proteasome inhibition in human multiple myeloma cells, Proc Natl Acad Sci U S A, 99, 14374, 10.1073/pnas.202445099 Hideshima, 2003, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341, Blood, 101, 1530, 10.1182/blood-2002-08-2543 Fanucchi, 2005, Bortezomib ± docetaxel in previously treated patients with advanced non–small cell lung cancer, Proc Am Soc Clin Oncol, 23, 629s Ling, 2003, Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines, Clin Cancer Res, 9, 1145 Chang, 1998, MDM2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway, Cell Growth Differ, 9, 79 An, 2000, Protease inhibitor-induced apoptosis, Leukemia, 14, 1276, 10.1038/sj.leu.2401812 Younes, 2003, Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy, J Clin Oncol, 21, 3526, 10.1200/JCO.2003.09.037 Ashkenazi, 2002, Targeting death and decoy receptors of the tumour-necrosis factor superfamily, Nat Rev Cancer, 2, 420, 10.1038/nrc821 Bonomi, 2005, Results of a phase -2 trial of HGS-ETR1 (agonistic human monochondrial antibody to TRAIL receptor1) in subjects with relapsed NSCLC, Lung Cancer, 49, S237, 10.1016/S0169-5002(05)80953-5 Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest, 104, 155, 10.1172/JCI6926 Chuntharapai, 2001, Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4, J Immunol, 166, 4891, 10.4049/jimmunol.166.8.4891 Choi, 2002, Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells, Mol Cell Biol, 22, 724, 10.1128/MCB.22.3.724-736.2002 Gliniak, 1999, Tumor necrosis factor-related apoptosis-inducing ligand’s antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11, Cancer Res, 59, 6153 Johnson, 2004, Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by Taxol and carboplatin, Proc Am Assoc Cancer Res, 45, 200 Lawrence, 2001, Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions, Nat Med, 7, 383, 10.1038/86397 Mitsiades, 2001, TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma, Blood, 98, 795, 10.1182/blood.V98.3.795 Nagane, 2000, Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res, 60, 847 Pitti, 1996, Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family, J Biol Chem, 271, 12687, 10.1074/jbc.271.22.12687 Tanaka, 2000, Expression and antitumor effects of TRAIL in human cholangiocarcinoma, Hepatology, 32, 523, 10.1053/jhep.2000.9716 Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat Med, 5, 157, 10.1038/5517 Wiley, 1995, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673, 10.1016/1074-7613(95)90057-8 Gerber, 2004, Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells, Eur Respir J, 24, 40, 10.1183/09031936.04.00079203